We hypothesized that dual p42-MAPK and Rheb knockdown would boost the toxic effect of DTX, a taxane drug that inhibits microtubule depolymerization, which is one of the first-line antitumoral drugs used in prostate cancer treatment. Here, RHEB is linked to prostate carcinoma.